Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LUNG is 35.82M, and currently, short sellers hold a 2.28% ratio of that floaft. The average trading volume of LUNG on December 13, 2024 was 220.16K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LUNG) stock’s latest price update
Pulmonx Corp (NASDAQ: LUNG)’s stock price has gone rise by 0.74 in comparison to its previous close of 6.05, however, the company has experienced a -4.77% decrease in its stock price over the last five trading days. zacks.com reported 2024-11-21 that The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LUNG’s Market Performance
LUNG’s stock has fallen by -4.77% in the past week, with a monthly drop of -9.30% and a quarterly drop of -25.21%. The volatility ratio for the week is 7.53% while the volatility levels for the last 30 days are 7.15% for Pulmonx Corp The simple moving average for the past 20 days is -4.32% for LUNG’s stock, with a -17.63% simple moving average for the past 200 days.
Analysts’ Opinion of LUNG
Many brokerage firms have already submitted their reports for LUNG stocks, with Citigroup repeating the rating for LUNG by listing it as a “Neutral.” The predicted price for LUNG in the upcoming period, according to Citigroup is $7.50 based on the research report published on December 11, 2024 of the current year 2024.
Lake Street, on the other hand, stated in their research note that they expect to see LUNG reach a price target of $12. The rating they have provided for LUNG stocks is “Buy” according to the report published on June 04th, 2024.
Wells Fargo gave a rating of “Equal Weight” to LUNG, setting the target price at $14 in the report published on February 23rd of the current year.
LUNG Trading at -7.42% from the 50-Day Moving Average
After a stumble in the market that brought LUNG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.91% of loss for the given period.
Volatility was left at 7.15%, however, over the last 30 days, the volatility rate increased by 7.53%, as shares sank -6.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.10% lower at present.
During the last 5 trading sessions, LUNG fell by -5.31%, which changed the moving average for the period of 200-days by -34.27% in comparison to the 20-day moving average, which settled at $6.37. In addition, Pulmonx Corp saw -52.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUNG starting from Rose Geoffrey Beran, who sale 4,376 shares at the price of $6.18 back on Dec 02 ’24. After this action, Rose Geoffrey Beran now owns 291,057 shares of Pulmonx Corp, valued at $27,065 using the latest closing price.
Lehman David Aaron, the GENERAL COUNSEL of Pulmonx Corp, sale 5,497 shares at $6.19 during a trade that took place back on Dec 02 ’24, which means that Lehman David Aaron is holding 197,851 shares at $34,006 based on the most recent closing price.
Stock Fundamentals for LUNG
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.74 for the gross margin
The net margin for Pulmonx Corp stands at -0.72. The total capital return value is set at -0.38. Equity return is now at value -51.99, with -32.41 for asset returns.
Based on Pulmonx Corp (LUNG), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 0.4. The interest coverage ratio of the stock is -15.82.
Currently, EBITDA for the company is -55.09 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 2.96. The receivables turnover for the company is 6.43for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.70.
Conclusion
In a nutshell, Pulmonx Corp (LUNG) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
